CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewDinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activityAntitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancerCell cycle proteins as promising targets in cancer therapyCyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.Intersection of mitochondrial fission and fusion machinery with apoptotic pathways: Role of Mcl-1.Mcl-1 inhibitors: a patent review.The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.Family matters: How MYC family oncogenes impact small cell lung cancer.Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.The emerging roles of CDK12 in tumorigenesis.Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple negative breast cancer.Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183.CDK9 inhibitors in acute myeloid leukemia.Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC).Advances in the Treatment of Pediatric Bone Sarcomas.Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
P2860
Q27304386-DCCC87C6-2AB6-48B3-AFC2-F4837588F5B6Q30843418-7A692969-0D0B-4591-8E0B-FD2CB6BEF28BQ36020882-C6B6E2D9-9157-4FF1-90A8-A9CA866293CDQ36846723-5A6CBE5D-7F8B-41A4-89FD-96F382F68AE9Q36962507-859CC23C-8888-41C7-B473-A69D63F60441Q37063908-8F4EC6A2-B23C-4E40-8563-AD1D23F6BABBQ37399378-7870120A-E7B5-4C4D-9CB8-4E5A742D6D23Q37636710-3407A7B9-5ABA-4CFC-A09F-5B1C5C1D0D76Q37693690-C1F6E1B3-3AD6-4483-A460-DEBF5764FA4AQ37716464-8D7279E7-94D8-4F91-8B8B-D15CAC48F15FQ38712214-BAB354CB-4720-4DCA-8592-A87AA057EC6BQ38755091-51429303-E125-4A5F-AF3D-E5A40A056491Q38806786-1607F8E0-DAE5-43BE-9352-C56F8F14F1ACQ38846360-A19276DF-41ED-4559-85A2-E2E9432264F5Q38981785-A06DD1DA-AD41-4613-AB06-8CB1D2C927C8Q39005055-785E79AA-4FF1-40EE-9BA5-D65C064D4903Q39454070-3FB445B1-259A-4B65-9A72-684A85CC5B13Q40041197-3FF76761-A500-4D0B-BDFA-B5DA3E74CD89Q42367759-A6C5A835-3A46-4F4C-847A-344D6664DD26Q42566009-FEEF0E3B-C86D-4239-8EEC-32C8EB7D840AQ47155353-C0B24E3E-47F4-472B-8E8C-FE1B13B6CE80Q47611731-5496F0BD-37A4-4FE7-B0F9-7DAF43824056Q48588785-7890B36A-33BC-4CB1-B5A5-614520DF940CQ50031768-E18093D0-F4EF-4253-9E9F-DEEC76DB8615Q50056226-D6B61EB0-3EA9-460A-9EED-3CB2F201F09BQ50318294-E5372850-5903-4C50-B0C0-ADEAEA8463C9Q50932257-47D5CAAA-586E-45E7-9376-D453A20A0FFFQ50969326-89F409A2-0829-4233-8706-12D766679BAAQ57270689-91364C8A-3BC4-49BC-AF75-CEB691A002C6
P2860
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CDK9 inhibition by dinaciclib ...... riven B-cell lymphoma in vivo.
@en
CDK9 inhibition by dinaciclib ...... riven B-cell lymphoma in vivo.
@nl
type
label
CDK9 inhibition by dinaciclib ...... riven B-cell lymphoma in vivo.
@en
CDK9 inhibition by dinaciclib ...... riven B-cell lymphoma in vivo.
@nl
prefLabel
CDK9 inhibition by dinaciclib ...... riven B-cell lymphoma in vivo.
@en
CDK9 inhibition by dinaciclib ...... riven B-cell lymphoma in vivo.
@nl
P2093
P2860
P50
P356
P1433
P1476
CDK9 inhibition by dinaciclib ...... driven B-cell lymphoma in vivo
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2015.10
P577
2014-01-12T00:00:00Z
P5875
P6179
1013452859